Tex. Gov't Code § 549.0105
Current with legislation from the 2023 Regular and Special Sessions signed by the Governor as of November 21, 2023.
Before or during supplemental rebate agreement negotiations for a prescription drug being considered for the preferred drug list, the commission shall disclose to pharmaceutical manufacturers any clinical edits or clinical protocols that may be imposed on drugs within a particular drug category that are placed on the preferred drug list during the contract period. Clinical edits may not be imposed for a preferred drug during the contract period unless the disclosure is made. (Gov. Code, Sec. 531.070(n).)
Tex. Gov't. Code § 549.0105